Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
Read more at globenewswire.com
